不同治疗前风险分层工具预测前列腺癌死亡的头对头全国队列比较
该全国性队列研究纳入PCBaSe 4.0中154 811例非转移性前列腺癌男性,主要分析139 515例,比较D'Amico、NICE、EAU、GUROC、AUA、NCCN、CPG、CAPRA评分和MSKCC列线图预测前列腺癌死亡的表现。10年随访C-index为0.73-0.81,MSKCC列线图(0.81)、CAPRA评分(0.80)和CPG系统(0.78)表现最佳。
要点
- MSKCC列线图、CAPRA评分和CPG系统预测前列腺癌死亡优于D'Amico及其衍生系统。
- 10年随访C-index范围0.73-0.81,最佳工具为MSKCC列线图(0.81)。
- 预测累积发生率与观察值接近,5年时略有低估。
核心结论
- MSKCC列线图、CAPRA评分和CPG风险分组系统在区分前列腺癌死亡方面优于D'Amico及D'Amico衍生系统(NICE、GUROC、EAU、AUA和NCCN)。
研究设计与样本
- 全国性队列研究,纳入Prostate Cancer data Base Sweden(PCBaSe)4.0中1998-2016年诊断的非转移性前列腺癌男性154 811例,随访至2016年。
- 主要分析纳入139 515例男性,随访期间15 961例死于前列腺癌。
主要发现
- 10年随访C-index范围为0.73(95%CI:0.72-0.73)至0.81(95%CI:0.80-0.81)。
- MSKCC列线图C-index为0.81(95%CI:0.80-0.81),CAPRA评分为0.80(95%CI:0.79-0.81),CPG系统为0.78(95%CI:0.78-0.79)。
- 按主要治疗和诊断年份分层分析后,工具间的性能排序保持不变。
- 预测累积发生率与观察值接近,5年时略有低估。
临床怎么用
- 这些工具的使用可能改善临床决策。
局限性
- 研究仅基于瑞典环境(即病例组合)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Numerous pretreatment risk classification tools are available for prostate cancer. Which tool is best in predicting prostate cancer death is unclear. OBJECTIVE: To systematically compare the prognostic performance of the most commonly used pretreatment risk stratification tools for prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: A nationwide cohort study was conducted, including 154 811 men in Prostate Cancer data Base Sweden (PCBaSe) 4.0 diagnosed with nonmetastatic prostate cancer during 1998-2016 and followed through 2016. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We compared the D'Amico, National Institute for Health and Care Excellence (NICE), European Association of Urology (EAU), Genito-Urinary Radiation Oncologists of Canada (GUROC), American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), and Cambridge Prognostic Groups (CPG) risk group systems; the Cancer of the Prostate Risk Assessment (CAPRA) score; and the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram in predicting prostate cancer death by estimating the concordance index (C-index) and the observed versus predicted cumulative incidences at different follow-up times. RESULTS AND LIMITATIONS: A total of 139 515 men were included in the main analysis, of whom 15 961 died from prostate cancer during follow-up. The C-index at 10 yr of follow-up ranged from 0.73 (95% confidence interval [CI]: 0.72-0.73) to 0.81 (95% CI: 0.80-0.81) across the compared tools. The MSKCC nomogram (C-index: 0.81, 95% CI: 0.80-0.81), CAPRA score (C-index: 0.80, 95% CI: 0.79-0.81), and CPG system (C-index: 0.78, 95% CI: 0.78-0.79) performed the best. The order of performance between the tools remained in analyses stratified by primary treatment and year of diagnosis. The predicted cumulative incidences were close to the observed ones, with some underestimation at 5 yr. It is a limitation that the study was conducted solely in a Swedish setting (ie, case mix). CONCLUSIONS: The MSKCC nomogram, CAPRA score, and CPG risk grouping system performed better in discriminating prostate cancer death than the D'Amico and D'Amico-derived systems (NICE, GUROC, EAU, AUA, and NCCN). Use of these tools may improve clinical decision making. PATIENT SUMMARY: There are numerous pretreatment risk classification tools that can aid treatment decision for prostate cancer. We systematically compared the prognostic performance of the most commonly used tools in a large cohort of Swedish men with prostate cancer. The Memorial Sloan Kettering Cancer Center nomogram, Cancer of the Prostate Risk Assessment score, and Cambridge Prognostic Groups performed best in predicting prostate cancer death. The use of these tools may improve treatment decisions.
引用
- Zelic R, Garmo H, Zugna D, et al. Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study. Eur Urol. 2019. PMID: 31606332. doi:10.1016/j.eururo.2019.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。